March 30, 2021By Mel J. YeatesMoving against mucopolysaccharidosisEMA grants Orphan Drug designation to JR-171 for the treatment of mucopolysaccharidosis type I
March 26, 2021By GlobalData/DDNews StaffReal world evidence market is growing fastApplications of RWE-based insights range from drug discovery to supporting regulatory decision-making
Preclinical ResearchMarch 26, 2021By Peter T. KissingerTeaming science while spreading risk—It’s a lottery that worksIt takes real strength of character to accept the high risk in pharma and biotech and not be psychologically crippled by it
March 26, 2021By Jeffrey BouleyCOVID-19: Side effects and unintended benefitsThe pandemic has not been good to us, but some good things might come out of it
Other Internal MedicineMarch 25, 2021By Lori LeskoGrading non-alcoholic steatohepatitisMedian Technologies teams up with UC San Diego on diagnosing liver fibrosis severity in NASH patients
March 25, 2021By Lori LeskoGo with your gut (microbiome)Study details results on a new method for treating immunotherapy-resistant melanoma patients
March 25, 2021By Mel J. YeatesJSP191 data positive for cell transplantationThe anti-CD117 antibody is being evaluated as a conditioning agent prior to blood stem cell transplantation
March 25, 2021By Ilene SchneiderClinical trial transformationDecentralization accelerates during pandemic, with positive results
March 22, 2021By DDN StaffA new option for EPIAzurRx completes enrollment in Phase 2 clinical trial of MS1819 in combination with PERT to treat cystic fibrosis patients with severe exocrine pancreatic insufficiency
Other Internal MedicineMarch 19, 2021By DDN StaffA new way to treat gingivitisPositive top-line Phase 2 results for AMY-101 in adults with periodontal inflammation and gingivitis